‘Historic’ White House Announcement on Autism and Tylenol Causes Confusion
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
Drugs
41 - 60 of 1,296 Results
-
-
Off-Label Drug Helps One Boy With Autism Speak, Parents Say. But Experts Want More Data.
This week, the FDA began the process of approving leucovorin, an inexpensive, generic drug derived from folic acid, to help children diagnosed with autism.
Public Health Further Politicized Under the Threat of More Firings
Episode 415In a rambling news conference that shocked public health experts, President Donald Trump — without scientific evidence — blamed the over-the-counter drug acetaminophen, and too many childhood vaccines, for the increase in autism diagnoses in the U.S. That came days after a key immunization advisory panel, newly reconstituted with vaccine doubters, changed several long-standing recommendations. Former Centers for Disease Control and Prevention official Demetre Daskalakis joins KFF Health News’ Julie Rovner to discuss those stories. Meanwhile, Sandhya Raman of CQ Roll Call and Anna Edney of Bloomberg News join Rovner with the rest of the news, including a threat by the Trump administration to fire rather than furlough federal workers if Congress fails to fund the government beyond the Oct. 1 start of the new fiscal year.
-
Trump Claims ‘No Downside’ to Avoiding Tylenol During Pregnancy. He’s Wrong.
Doctors say acetaminophen, the main ingredient in Tylenol, is safe to take during pregnancy. Other over-the-counter pain relievers such as aspirin and ibuprofen aren’t recommended because they can harm fetal development. Untreated fever in pregnancy can pose maternal and fetal health risks.
-
‘Sick to My Stomach’: Trump Distorts Facts on Autism, Tylenol, and Vaccines, Scientists Say
The White House’s autism announcement exaggerates links to Tylenol, misleads on vaccines, and sets back the field by ignoring decades of research, scientists say.
By Amy Maxmen -
Why Are More Older People Dying After Falls?
Some researchers suspect that rising prescription drug use may explain a disturbing trend.
By Paula Span -
Under Trump, FDA Seeks To Abandon Expert Reviews of New Drugs
Advisory committee meetings help FDA scientists make decisions and increase public understanding of drug regulation, and abandoning them doesn’t make sense, former officials said.
By Arthur Allen Countdown to Government Shutdown
Episode 413With less than three weeks before the deadline to pass legislation to keep the federal government running, lawmakers are still far apart on a strategy. Democrats hope Republicans will agree to extend expanded tax credits for the Affordable Care Act as part of a compromise, but so far Republicans are not negotiating. Meanwhile, HHS Secretary Robert F. Kennedy Jr. released his long-awaited “Make America Healthy Again” report, with few specific action items. Anna Edney of Bloomberg News, Sandhya Raman of CQ Roll Call, and Lauren Weber of The Washington Post join KFF Health News’ Julie Rovner to discuss these stories and more.
On Capitol Hill, RFK Defends Firings at CDC
Episode 412A combative Robert F. Kennedy Jr, the U.S. secretary of health and human services, appeared before a Senate committee Thursday, defending his firing of the newly confirmed director of the Centers for Disease Control and Prevention as well as other changes that could limit the availability of vaccines. Meanwhile, Congress has only a few weeks to complete work on annual spending bills to avoid a possible government shutdown and to ward off potentially large increases in premiums for Affordable Care Act health plans. Jessie Hellmann of CQ Roll Call, Sarah Karlin-Smith of Pink Sheet, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews KFF Health News’ Tony Leys, who discusses his “Bill of the Month” report about a woman’s unfortunate interaction with a bat — and her even more unfortunate interaction with the bill for her rabies prevention treatment.
-
As Insurers Struggle With GLP-1 Drug Costs, Some Seek To Wean Patients Off
Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss. But a growing number of researchers, payers, and providers are challenging that consensus and exploring whether — and how — to taper patients off expensive GLP-1 drugs.
-
Senior CDC Officials Resign After Monarez’s Ouster, Citing Concerns Over Scientific Independence
Four senior officials with the Centers for Disease Control and Prevention announced their resignations in recent days, citing what they described as growing political interference in the agency's scientific work, particularly regarding vaccines.
-
FTC Has Long Said Products Must Back Up Health Claims. A MAHA Lawsuit Would Upend That.
Xlear, a maker of xylitol gum, has sued the Federal Trade Commission, saying the onus should be on government to prove that ingredients don’t live up to advertised claims. RFK Jr.’s “medical freedom” allies have rallied to the cause.
By Arthur Allen -
Breaking Down Why Medicare Part D Premiums Are Likely To Go Up
Insurers will take drug costs, frequency of use, and other factors into account as they set premium amounts for the 2026 plan year.
Kennedy Cancels Vaccine Funding
Episode 409The Health and Human Services secretary is winding down nearly $500 million in mRNA research funding, citing false claims that the technology is ineffective against respiratory illnesses — and notching a victory for critics of the covid vaccines. And President Donald Trump is demanding drugmakers drop their prices, quickly, but it’s unclear how he could make them comply. Lauren Weber of The Washington Post, Sandhya Raman of CQ Roll Call, and Sarah Karlin-Smith of the Pink Sheet join KFF Health News’ Emmarie Huetteman to discuss these stories and more.
-
Chronically Ill? In Kennedy’s View, It Might Be Your Own Fault
In their zeal to “Make America Healthy Again,” top Trump administration officials depict patients and the doctors who treat them as partly responsible for whatever ails them.
Here Come the ACA Premium Hikes
Episode 407Medicaid may have monopolized Washington’s attention lately, but big changes are coming to the Affordable Care Act as well. Meanwhile, Americans are learning more about what’s in Trump’s big budget law, and polls suggest many don’t like what they see. Julie Appleby of KFF Health News, Jessie Hellmann of CQ Roll Call, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews historian Jonathan Oberlander to mark Medicare’s 60th anniversary.
The Senate Saves PEPFAR Funding — For Now
Episode 406The Senate narrowly approved the Trump administration’s request to claw back about $9 billion for foreign aid and public broadcasting but refused to cut funding for the international AIDS/HIV program PEPFAR. Meanwhile, a federal appeals court ruled that West Virginia can ban the abortion pill mifepristone, which could allow states to block other FDA-approved drugs. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, Shefali Luthra of The 19th, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more.
-
Maybe It’s Not Just Aging. Maybe It’s Anemia.
Significant numbers of older people have the condition. Many find relief with an effective treatment that is being more widely prescribed.
By Paula Span The Prescription Drug Playbook, Part II
Season 13, Episode 10In this second part of a two-part series on dealing with the high price of prescription drugs, experts share their insider tips.
-
Journalists Assess Health Impacts of Trump’s Megabill, Who Will Feel Them, and When
KFF Health News journalists made the rounds on national and regional media this week to discuss topical stories. Here’s a collection of their appearances.